Melasma, Post-inflammatory Hyperpigmentation, Solar Lentigo
Conditions
Brief summary
The study aims to evaluate the efficacy of a facial sunscreen under two experimental conditions-untinted and tinted-in improving facial spots (melasma and solar lentigines/post-inflammatory hyperpigmentation) after 8 weeks of product use under normal conditions by adult participants.
Interventions
OTHERSunscreen untinted
Participants will apply the facial sunscreen on the face at least twice daily for 56 days
OTHERSunscreen tinted
Participants will apply the facial sunscreen on the face at least twice daily for 56 days
Sponsors
Kenvue Brands LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Able to understand and follow study instructions 2. Fitzpatrick skin types I-VI 3. Presence of facial hyperpigmentation, such as: * Mild to moderate melasma, or * Visible dark spots (e.g., solar lentigines or post-inflammatory hyperpigmentation) 4. Willing to comply with study procedures and product use 5. For subjects in applicable groups: willing to use assigned sunscreen product
Exclusion criteria
1. Known sensitivity or allergy to cosmetic or skincare products 2. Skin conditions or lesions in the study area that could interfere with evaluation (e.g., active dermatitis, infections, significant irritation, or extensive scarring) 3. Use of medications or products that may interfere with study evaluations 4. Recent cosmetic or dermatological procedures in the study area (e.g., chemical peels, laser treatments, invasive procedures) 5. Excessive sun exposure or use of tanning beds immediately prior to or during the study 6. Pregnancy or intention to become pregnant during the study 7. Participation in another clinical study within a recent period 8. Any condition or situation that, in the investigator's judgment, may interfere with study participation or evaluation of results
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical efficacy of change in hyperpigmentation assessed via dermatological evaluation | Before and after Visit 2 (14+2 days), Visit 3 (28+2 days), and Visit 4 (56+2 days) of IP use | — |
| Instrumental measurements with the Chroma Meter CR 400 (Konica Minolta) | Before and after Visit 2 (14+2 days), Visit 3 (28+2 days), and Visit 4 (56+2 days) of IP use | Measurements will be taken using the Chroma Meter® CR 400 to evaluate the color intensity of the dark spot (Melasma, Solar Lentigo, or Post-Inflammatory Hyperpigmentation) in comparison to the measurement of an adjacent area (without a spot). |
| Capture of facial images using the Visia-CR® Facial Imaging Booth (Canfield Scientific, Inc.) | Before, immediately after the first application, and after Visit 2 (14+2 days), Visit 3 (28+2 days), and Visit 4 (56+2 days) of IP use | Facial images will be captured using the Visia CR® Facial Imaging Booth (Canfield Scientific, Inc.) for analysis of the intensity and size of the spot (Melasma, Solar Spot, or Post-Inflammatory Hyperpigmentation), as well as the overall uniformity of skin tone. |
| Participants' quality of life regarding facial spots for participants with Melasma assessed through a Quality of Life Questionnaire (MELASQoL) | Before and after Visit 2 (14+2 days), Visit 3 (28+2 days), and Visit 4 (56+2 days) of IP use | Melasma Quality of Life Scale (MELASQoL) will only be answered by participants enrolled in Melasma group. The participant will answer a questionnaire with 10 questions regarding the condition of their skin, using a rating scale from 1 to 7, in which: 1 means "not at all bothered" and 7 means "bothered all the time". A total score will be generated by summing the scores of the 10 questions answered by the participant. The total score ranges from 10 to 70. The lower the score, the better the participant's quality of life. |
| Participants' quality of life regarding facial spots for participants with Solar Lentigo or Post-Inflammatory Hyperpigmentation assessed through a Quality of Life Questionnaire (DLQI) | Before and after Visit 2 (14+2 days), Visit 3 (28+2 days), and Visit 4 (56+2 days) of IP use | Dermatology Life Quality Index (DLQI) will only be answered by participants selected for the Solar Lentigo/PIH Group. The participant will answer a questionnaire with 10 questions regarding the impact of their skin on their quality of life. Each question is scored on a four-point Likert scale: very much = 3 points, much = 2 points, a little = 1 point and nothing/not relevant = 0 points. Questions answered as nothing and not relevant are equivalent to 0 points. The total score ranges from 0 to 30. The lower the score, the better the participant's quality of life. |
| Perceived efficacy assessed through perception questionnaires completed by the research participants | After Visit 2 (14+2 days), Visit 3 (28+2 days), and Visit 4 (56+2 days) of IP use | Participants will answer a questionnaire evaluating their individual opinion about the Investigational Product used. Questionnaire consists of 9 questions which should be answered in a 5-point scale of agreement (such as ranging from "Strongly Disagree" to "Strongly Agree"). |
| Open emotional testimonial written by the participant at the end of IP use | After Visit 4 (56+2 days) of IP use | Consists of an open-ended, narrative question in which the participant provides a brief statement regarding their experience with the use of their respective Investigational Product. |
Countries
Brazil
Contacts
CONTACTKenvue Global Clinical Operations
Outcome results
None listed